Safety and Efficacy Study of Besivance™ for Treatment of Congenital Nasolacrimal Duct Obstruction in Children
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The goal of the study is to evaluate the application of Besivance™ (besifloxacin ophthalmic
suspension, 0.6%) to treat congenital nasolacrimal duct obstruction in children. The
hypothesis of the study is that Besivance™ is as safe and effective as the current standard
of care for the treatment of nasolacrimal duct obstruction in children.
Phase:
Phase 1
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborator:
Bausch & Lomb Incorporated
Treatments:
7-(3-aminohexahydro-1H-azepin-1-yl)-8-chloro-1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid Besifloxacin Fluoroquinolones Ophthalmic Solutions Polymyxin B Polymyxins Trimethoprim